Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease.

Détails

ID Serval
serval:BIB_8BDEC3D75429
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease.
Périodique
Journal of neurology, neurosurgery, and psychiatry
Auteur(s)
Ribi C., Sztajzel R., Delavelle J., Chizzolini C.
ISSN
0022-3050 (Print)
ISSN-L
0022-3050
Statut éditorial
Publié
Date de publication
12/2005
Peer-reviewed
Oui
Volume
76
Numéro
12
Pages
1733-1735
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
Behçet disease is a chronic relapsing inflammatory condition, predominantly affecting young adults, characterised by recurrent bipolar aphtae and systemic manifestations for which tumour necrosis factor (TNF) alpha blockade has recently emerged as an effective treatment. We report the case of a patient presenting with mucocutaneous and ocular manifestations who in the course of his disease developed CNS parenchymal involvement. While being treated with pulsed cyclophosphamide and corticosteroids, he suffered a relapse of his CNS involvement that was efficaciously controlled by infliximab. No disease activity was observed during a full year of TNF blockade, associated with azathioprine, colchicine, and corticosteroids. However, 7 months after the last administration of infliximab and still under immunosuppressant agents, CNS lesions recurred. Infliximab was successfully reintroduced and since continued with no side effects. The sequence of events observed in this patient suggests that TNF blockade is efficacious in suppressing neuro-Behçet disease and once introduced should be maintained for a prolonged period of time.
Mots-clé
Adult, Antibodies, Monoclonal/therapeutic use, Antirheumatic Agents/therapeutic use, Behcet Syndrome/drug therapy, Behcet Syndrome/immunology, Behcet Syndrome/pathology, Cyclophosphamide/pharmacology, Cyclophosphamide/therapeutic use, Humans, Immunosuppressive Agents/pharmacology, Immunosuppressive Agents/therapeutic use, Infliximab, Male, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Open Access
Oui
Création de la notice
01/07/2020 11:49
Dernière modification de la notice
02/07/2020 9:32
Données d'usage